PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11471768

Epilepsy.

S C Schachater
View original source ↗Export metadata ↓

Abstract

The successful management of epilepsy requires a thorough and individualized approach that accurately establishes the patient's seizure type(s) and, when appropriate, epilepsy syndrome. Selection of pharmacologic and nonpharmacologic therapy should be rational and tailored to each patient. In this manner, clinicians are able to take advantage of new treatments to minimize the impact of seizures, treatment side effects, and epilepsy-related psychosocial difficulties on their patients, thereby enabling them to function in society at the highest possible level.

Explore related subjects

AnticonvulsantsBrainElectric Stimulation TherapyEpilepsyHumansVagus NerveJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S C Schachater. 2001. Epilepsy.. https://doi.org/10.1016/s0733-8619(05)70005-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Properties of enteric coated sodium valproate pellets.

The influence of subcoat application and micro-environmental pH on the dissolution properties of enteric coated sodium valproate pellets was investigated. The pellets were prepared by solution-layering or wet-mass extrusion-spheronization methods. In order to pass the USP enteric test, the solution-layered and wet-mass extruded pellets required 35 and 25% weight gain of Eudragit L 30D-55, respectively. The application of a subcoat of either Methocel-E5 (HPMC) or Opadry AMB to the pellets resulted in a delay in sodium valproate release in 0.1N HCl. Further delay in drug release was observed when citric acid was present in a HPMC subcoat or when added to the core pellet formulation. The amount of drug released from coated pellets was a function of the level of citric acid in the pellet core or subcoat and subsequent micro-environmental pH of the pellets. Citric acid exerted a plasticizing effect on the enteric polymer film and improved film formation and polymer coalescence. When greater than 10% (w/w) citric acid was present in the pellets, a decrease in drug content was observed due to the conversion of sodium valproate to the volatile compound, valproic acid. Pellets containing less than 10% (w/w) citric acid maintained potency during processing.

Anticonvulsants↗
PubMed2003

Determination of vigabatrin by capillary electrophoresis with laser-induced fluorescence detection.

A new analytical method for vigabatrin based on capillary electrophoretic separation and laser-induced fluorescence detection has been developed. 5-Carboxytetramethylrhodamine succinimidyl ester was used for precolumn derivatization of the non-fluorescent drug. Optimal separation and detection were obtained with an electrophoretic buffer of 50 mM sodium borate (pH9.5) containing 10 mM sodium dodecyl sulfate and a green He-Ne laser (excitation at 543.5 nm, emission at 589 nm). The concentration limit of detection in aqueous solution was 24 nM. Combined with a simple cleanup procedure, this method can be applied to the determination of vigabatrin in human plasma. A calibration curve ranging from 1.5 to 200 microM shown to be linear. Both the within-day and day-to-day reproducibilities and accuracies were less then 14.3% and 4.9% respectively. The limit of detection of vigabatrin in plasma was about 0.13 microM

Anticonvulsants↗